Pramlintide in the treatment of diabetes mellitus

BioDrugs

Volumn 22, Issue 6, 2008, Pages 375-386

  Edelman, Steve ^a   Maier, Holly ^b   Wilhelm, Ken ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Amylin agonists, general; Obesity; Pramlintide, therapeutic use; Research and development; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

AMYLIN; INSULIN; INSULIN LISPRO; PLACEBO; PRAMLINTIDE;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG MECHANISM; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING;

AMYLOID; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY;

EID: 56049114898     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/0063030-200822060-00004     Document Type: Review

References (72)

1. International Diabetes Federation. Did you know? [online]. Available from URL: http://www.idf.org/home/index.cfm?node=37 [Accessed 2008 Jun 11]
2. American Diabetes Association. Standards of medical care in diabetes: 2008. Diabetes Care 2008; 31 Suppl. 1: S12-54
3. Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second β-cell hormone. Diabetes Technol Ther 2002; 4 (2): 175-89
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329 (14): 977-86
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837-53
6. Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab 2007 Jan; 9 (1): 96-102
7. Purnell J, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003; 2 (1): 33-47
8. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357 (17): 1716-30
9. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005 Dec; 28 (12): 2948-61
10. Buse JB, Ginsbert HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007 Jan; 30 (1): 162-72
11. Young AA, Gedulin B, Vine W, et al. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1995; 38 (6): 642-8
12. Gedulin B, Percy A, Jodka C, et al. Studies using neutralizing antibody and the antagonist AC187 reveal that endogenous amylin inhibits glucagon secretion [abstract no. 1179]. Diabetologia 1997; 40 Suppl. 1: A300
13. Bhavsar S, Watkins J, Young A. Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol Behav 1998; 64 (4): 557-61
14. Kruger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ 1999; 25 (3): 389-97; quiz 398
15. Nowak TV, Johnson CP, Wood CM, et al. Evidence for accelerated gastric emptying in asymptomatic patients with insulin-dependent diabetes mellitus [abstract]. Gastroenterology 1990; 98 (5 Pt 2): A378
16. Phillips WT, Schwartz JG, McMahan CA. Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients. J Nucl Med 1992; 33 (8): 1496-500
17. Maggs D, MacDonald I, Nauck MA. Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes. Diabetes Obes Metab 2008; 10 (1): 18-33
18. Schvarcz E, Palmer M, Aman J, et al. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997; 113 (1): 60-6
19. Bertin E, Schneider N, Abdelli N, et al. Gastric emptying is accelerated in obese type 2 diabetic patients without autonomic neuropathy. Diabetes Metab 2001 Jun; 27 (3): 357-64
20. Gedulin BR, Young AA. Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats. Diabetes 1998; 47 (1): 93-7
21. Unger RH, Orci L. The role of glucagon in the endogenous hyperglycemia of diabetes mellitus. Annu Rev Med 1977; 28: 119-30
22. Silvestre RA, Rodriguez-Gallardo J, Jodka C, et al. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol Endocrinol Metab 2001; 280 (3): E443-9
23. Reidelberger RD, Arnelo U, Granqvist L, et al. Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 2001; 280 (3): R605-11
24. Granqvist L, Permert J, Arnelo U, et al. Effects of AC187, IAPP(8-37) and CGRP(8-37) on IAPP induced anorexia in rats [abstract no. 218]. Digestion 1997; 58 Suppl. 2: 55
25. Reidelberger RD, Haver AC, Arnelo U, et al. Amylin receptor blockade stimulates food intake in rats. Am J Physiol Regul Integr Comp Physiol 2004 Sep; 287 (3): R568-74
26. Amylin Pharmaceuticals Inc. Symlin™ (pramlintide acetate) injection [package insert]. San Diego (CA): Amylin Pharmaceuticals Inc., 2008 [online]. Available from URL: http://www.symlin.com/pdf/SYMLIN-pi-combined.pdf [Accessed 2008 Oct 28]
27. Maggs DG, Fineman M, Kornstein J, et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose timing study. Diabetes Metab Res Rev 2004 Jan-Feb 28; 20 (1): 55-60
28. Weyer C, Gottlieb A, Kim DD, et al. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care 2003 Nov; 26 (11): 3074-9
29. Edelman SV, Schroeder BE, Frias JP. Pramlintide acetate in the treatment of type 2 and type 1 diabetes mellitus. Exp Rev Endocrinol Metab 2007; 2: 9-18
30. Samsom M, Szarka LA, Camilleri M, et al. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol 2000; 278 (6): G946-51
31. Vella A, Lee JS, Camilleri M, et al. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol Motil 2002 Apr; 14 (2): 123-31
32. Fineman MS, Koda JE, Shen LZ, et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002; 51 (5): 636-41
33. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005 May; 48 (5): 838-48
34. Fineman M, Weyer C, Maggs DG, et al. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 2002 Sep; 34 (9): 504-8
35. Nyholm B, Orskov L, Hove K, et al. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 1999; 48 (7): 935-41
36. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease [published erratum appears in Diabetes 1996 Nov; 45 (11): 1655]. Diabetes 1995 Nov; 44 (11): 1249-58
37. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131 (4): 281-303
38. Hepburn DA, MacLeod KM, Pell AC, et al. Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med 1993 Apr; 10 (3): 231-7
39. Henry RR, Gumbiner B, Ditzler T, et al. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993 Jan; 16 (1): 21-31
40. Gurlek A, Erbas T, Gedik O. Frequency of severe hypoglycaemia in type 1 and type 2 diabetes during conventional insulin therapy. Exp Clin Endocrinol Diabetes 1999; 107 (3): 220-4
41. Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003 Mar; 26 (3): 784-90
42. Gottlieb A, Fineman M, Bahner A, et al. Pramlintide therapy in addition to insulin in type 2 diabetes: effect on metabolic control after 6 months [abstract no. 0873]. Diabetologia 1999; 42 Suppl. 1: A232
43. Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002; 4 (1): 51-61
44. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002; 25 (4): 724-30
45. Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year randomized controlled trial. Diabet Med 2004 Nov; 21 (11): 1204-12
46. Fineman M, Gottlieb A, Bahner A, et al. Pramlintide therapy in addition to insulin in type 1 diabetes: effect on metabolic control after 6 months [abstract no. 0872]. Diabetologia 1999; 42 Suppl. 1: A232
47. Guthrie R, Karl D, Wang Y, et al. In an open-label clinical study pramlintide lowered A1C, body weight, and insulin use in patients with type 1 diabetes failing to achieve glycemic targets with insulin therapy [abstract no. 478-P]. Diabetes 2005 Jun; 54 Suppl. 1: A118
48. Karl D, Philis-Tsimikas A, Darsow T, et al. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions and weight. Diabetes Technol Ther 2007 Apr; 9 (2): 191-9
49. Pullman J, Darsow T, Frias JP. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vasc Health Risk Manag 2006; 2 (3): 203-12
50. Riddle M, Frias J, Zhang B, et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 2007 Nov; 30 (11): 2794-9
51. Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006 Oct; 29 (10): 2189-95
52. Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004 Oct 25; 164 (19): 2090-5
53. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001 Dec 13; 414 (6865): 813-20
54. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006 Apr 12; 295 (14): 1681-7
55. Ceriello A, Lush CW, Darsow T, et al. Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes. Diabetes Metab Res Rev 2008 Feb; 24 (2): 103-8
56. Ceriello A, Piconi L, Quagliaro L, et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 2005 Mar; 28 (3): 632-7
57. Purnell JQ, Hokanson JE, Marcovina SM, et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998; 280 (2): 140-6
58. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003 Jan 28; 107 (3): 499-511
59. Lush C, Frias J, Zhang B, et al. Pramlintide, as an adjunct to basal insulin, reduced C-reactive protein, improved glycemic control, and led to weight loss in patients with type 2 diabetes [abstract no. 541-P]. Diabetes 2007 Jun; 56 Suppl. 1: A144
60. Lush C, Frias J, Nanayakkara N, et al. Effect of adjunctive pramlintide treatment on hsCRP and adiponectin levels in intensively treated patients with type 1 diabetes [abstract no. 0254]. Diabetologia 2006 Sep; 49 Suppl. 1: 160-1
61. Costacou T, Zgibor JC, Evans RW, et al. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2005 Jan; 48 (1): 41-8
62. Maahs DM, Ogden LG, Kinney GL, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005 Feb 15; 111 (6): 747-53
63. Marrero DG, Crean J, Zhang B, et al. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care 2007 Feb; 30 (2): 210-6
64. Rubin RR, Peyrot M. Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy. Curr Med Res Opin 2007; 23 (8): 1919-29
65. Jodka C, Green D, Young A, et al. Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve [abstract no. 867]. Diabetes 1996; 45 Suppl. 2: 235A
66. Lutz TA, Mollet A, Rushing PA, et al. The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats. Int J Obes Relat Metab Disord 2001; 25 (7): 1005-11
67. Mack C, Hoyt J, Moore C, et al. Sustained reduction in food intake and body weight in high fat-fed rats during 28-day amylin infusion [abstract no. 1690-P]. Diabetes 2003 Jun; 52 Suppl. 1: A389
68. Rushing PA. Central amylin signaling and the regulation of energy homeostasis. Curr Pharm Des 2003; 9 (10): 819-25
69. Rushing PA, Hagan MM, Seeley RJ, et al. Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology 2001; 142 (11): 5035-8
70. Smith SR, Blundell JE, Burns C, et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab 2007 Aug; 293 (2): E620-7
71. Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 2007 Aug; 92 (8): 2977-83
72. Amiel SA, Heller SR, MacDonald IA, et al. The effect of pramlintide on hormonal, metabolic, or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabetes Obes Metab 2005 Sep; 7 (5): 504-16